Showing 893 results
-
Media Release /Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the U.S.; Novartis to gain exclusive rights in CanadaNovartis retains commercial rights in rest of world; Amgen retains commercial rights…
-
Media Release /-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)-- R/r DLBCL, an…
-
Media Release /- 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis(1)- Data planned to be presented at a…
-
Media Release /- 83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data- Data evaluating 63…
-
Media Release /-- At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff-- Best ORR was 59%, with 43…
-
Media Release /- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
-
Media Release /- elevateMS study allows researchers to collect sensor-based movement data and symptoms directly from participants without the need for clinic visits- Study aims to improve understanding of daily…
-
Media Release /AMG 334 (erenumab) is an investigational therapy with a novel mechanism of action for migraine prevention for patients with high unmet needMigraine is associated with pain, disability and nearly $25…
-
Media Release /- Kiss This 4 MBC goes beyond raising awareness of metastatic breast cancer to generate an increase in public support and research funds for the estimated 155,000 people living with this disease in…
-
Media Release /- Cosentyx® (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1)- Landmark data show that PASI 90 and PASI…
